Glioblastoma Multiforme Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Temozolomide, Bevacizumab, Procarbazine, Lomustine, Carmustine), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Region Forecast 2019-2030

Glioblastoma multiforme treatment market size was valued at US$ 390.7 million in 2023 and is projected to reach US$ 363.4 million by 2030, growing at a CAGR of -0.8% from 2024-2030. Moreover, in the USA, US$ 70.8 million in 2023 and is projected to reach US$ 63.1 million by 2030, growing at a CAGR of -1.7%% from 2024-2030. The market is driven by the increasing prevalence of GBM, accounting for 45% of malignant brain tumors globally, and rising R&D investments, with initiatives like the U.S. Cancer Moonshot program targeting a 50% reduction in cancer deaths. Advances in precision medicine, including genomic profiling, and regulatory support like FDA orphan drug designations further drive growth.

However, challenges like high treatment cost exceeding $100,000 annually, low survival rates (7% five-year survival), and clinical trial complexities hinder progress. Severe side effects from existing therapies also limit adoption. Opportunities are emerging with immunotherapies such as CAR-T and cancer vaccines, as the immunotherapy market is projected to grow at a higher CAGR. Government funding, including €2 billion from the EU’s Horizon Europe, supports innovation. Expanding healthcare infrastructure in Asia-Pacific further fuels market potential. Trends include AI adoption for precision diagnostics, increasing reliance on combination therapies, and biomarker-driven treatments for better outcomes. Patient-centric virtual trials are also gaining traction, supported by NIH's $1 billion for tech-enabled clinical innovation. Combined, these dynamics position the GBM market for transformative growth in the coming decade.

Key Players

The glioblastoma multiforme treatment market share includes several companies, such as Merck & Co, Teva Pharmaceutical Industries, Arbor Pharmaceuticals, Sun Pharmaceutical Industries, Bayers Inc F. Hoffmann-Le Roche, Abbvie, Celldex Therapeutics, Exellixis, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, CANbridge Life Sciences, Apogenix, Pfizer and others. 

Key Takeaways

• Temozolomide is the market leader in the glioblastoma multiforme (GBM) treatment market, with the highest share in 2023.
• Hospital Pharmacies are the front-runners of the distribution channel segment with the highest contribution market share in 2023.
• Glioblastoma multiforme (GBM) is the most malignant brain tumor, accounting for almost 45% of malignant tumors worldwide.
• The annual incidence of approximately 3.2 per 100,000 people has driven the demand for innovative treatments for glioblastoma.

Facts and Figure

• Glioblastoma multiforme (GBM) is the most malignant brain tumor, accounting for almost 45% of malignant tumors worldwide.
• The annual incidence of approximately 3.2 per 100,000 people has driven the demand for innovative treatments for glioblastoma.
• A total of $6.8 billion in fiscal year 2022 appropriations is available to NCI, an increase of 5.7% or $366.6 million from the prior fiscal year, which includes $216 million in Cures Act funding.
• China increased its healthcare spending by 7% in 2023.

Key Developments

• Oct 2024: Sun Pharmaceutical Industries Limited and Philogen S.p.A have jointly announced that they have entered into a global licensing agreement to commercialize Philogen's specialty product, Fibromun (L19TNF). Fibromun, an innovative anti-cancer immunotherapy, is under registration trials by Philogen to be used in the treatment of soft tissue sarcoma and glioblastoma.
• 2020: Pfizer has announced the launch of three biosimilars, ZIRABEV (bevacizumab), RUXIENCE (rituximab) and TRAZIMERA (trastuzumab) in the United States. The medicines will be launched at a WAC as low as any currently available bevacizumab, rituximab or trastuzumab product, making them come to market highly discounted to the originator product.
• 2019: Bayer's Stivarga(R) (regorafenib) has become the first compound to be tested in a clinical trial platform that will explore new treatments for brain cancer, and announced the one-arm platform trial, GBM AGILE, (Glioblastoma Adaptive Global Innovative Learning Environment) opening enrollment to patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer.

Glioblastoma Multiforme Treatment Market Segmentation

By Product Type: Temozolomide is the market leader in the glioblastoma multiforme (GBM) treatment market, with the highest share in 2023. It is regarded as the gold standard for GBM treatment due to its efficacy, tolerability, and extensive use as a first-line therapy in combination with radiotherapy. Clinical studies show that Temozolomide improves progression-free survival rates by up to 37%, making it a go-to option for oncologists. Its global acceptance, coupled with the consistent availability and affordability compared to newer treatments, further solidifies this dominance.

By Distribution Channel: Hospital Pharmacies are the front-runners of the distribution channel segment with the highest contribution market share in 2023. There are good reasons for this, as treatment of GBM is mostly complex and often requires inpatient hospitalization and supervision by specialists. Most therapies for GBM are part of an integrated regimen that includes surgery and radiotherapy, mostly coordinated in hospitals. Furthermore, hospital pharmacies provide current drugs and research drugs, hence are the main source of treatments for GBM.